🔴 SKIN is trading 1.8% down today on profit-taking following its FDA-driven surge

SKIN is trading 1.8% down at $1.09 as the stock experiences a sharp pullback following its recent regulatory-driven rally.

• The stock previously surged 47.04% to $1.11 on July 7 after receiving FDA clearance for its SkinStylus device.
• Current price action is attributed to profit-taking following that significant spike, with no new company-specific catalysts reported.
• While broader markets are currently mixed to weaker, the move in SKIN is more directly tied to the prior approval than to general market trends.